posturing. IOP elevation is rarely a problem in the early postoperative period (Flaxel et al 2007). Disadvantages include the certainty of cataract formation and the fact that at some point, the oil must be removed if visual rehabilitation is to be accomplished (Thompson et al 1986). Pearson and colleagues (1993) studied the effect of silicone oil removal following diabetic vitrectomy and concluded that the eventual ﬁnal visual outcome in these eyes was encouraging in that once cataract and oil were removed; most eyes recovered the acuity achieved soon after initial vitrectomy. Good anatomical results in both groups can be ascribed to the improvement in vitrectomy equipment. The use of smaller 23 gauge vitrectors offers advantages of being less traumatizing and together with the high speed cutter effect enabled shaving of membranes very close to the retina with minimal trauma. Anterior peripheral retinal cryotherapy combined with cryotherapy of sclerotomy sites might be helpful adjunct procedures in diabetic vitrectomy for inhibi- tion of ﬁbrovascular ingrowth and prevention of recurrent vitreous hemorrhage (Yeh et al 2005). Mason and colleagues (2006) reported that using cryotherapy around sclerotomy sites and endolaser in a near-conﬂuent pattern helps to quell ﬁbrovascular ingrowth and subsequent hemorrhage. So, in the current study, preoperative IVA was helpful in achieving the surgical and anatomical goals by reducing the time of surgery, reducing the intraoperative and postopera- tive bleeding and reducing the frequency of using silicone oil with subsequent reduction of second surgery. The com- bination of therapies and interventions as they improve and evolve offers the potential to revolutionize the approach to the complications of diabetic eye disease. Disclosure The author has no proprietary or conﬂict of interest in this study. References Adamis AP, Shima DT. 2005. The role of vascular endothelial growth factor in ocular health and disease. Retina, 25:111–18. Aiello LP, Avery RL, Arrigg PG, et al. 1994. Vascular endothelial growth factor in ocular ﬂuid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med, 331:1480–7. Aiello LP, Brucker AJ, Chang S, et al. 2004. Evolving guidelines for intra- vitreal injections. Retina, 24:S3–19. Arevalo JF, Maia M, Flynn H, et al. 2008. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol, 92:213–16. Avery RL. 2006. Regression of retina and iris neovascularization after Intravitreal bevacizumab (Avastin) treatment. Retina, 26:352–3. Avery RL, Pieramici DJ, Rabina MD, et al. 2006. Intravitreal bevacizumab (Avastin) for neovascular age related macular degeneration. Ophthal- mology, 113:363–2. Clinical Ophthalmology 2008:2(4) Intravitreal bevacizumab and diabetic vitrectomy Blankenship GW. 1981. Stability of pars plana vitrectomy results for diabetic retinopathy complications: a comparison of 5 year and 6 month post- vitrectomy ﬁndings. Arch Ophthalmol, 99:1009–12. Blankenship GW, Machemer R. 1985. Long term diabetic vitrectomy results: report of 10 year follow up. Ophthalmology, 92:503–6. Beer PM, Wong S, Falk NS, et al. 2006. Vitreous levels of unbound beva- cizumab and unbound vascular endothelial growth factor in two human subjects. Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal Society, September 9–13, 2006; p. 77. Chen E, Park CH. 2006. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina, 26:699–70. de Bustros S, Glaser BM, Michels RG, et al. 1985a. Effect of epsilon- aminocaproic acid on postvitrectomy hemorrhage. Arch Ophthalmol, 103:219–21. de Bustros S, Glaser BM, Johnson MA. 1985b. Thrombin infusion for the control of intraocular bleeding during vitreous surgery. Arch Ophthal- mol, 103:837–9. [DRVS] Diabetic Retinopathy Vitrectomy Study Research Group. 1988. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial, Diabetic Vitrectomy Study report 3. Ophthalmology, 95:1307–20. Davidorf FH, MouserJG, Derick RJ. 2006. Rapid improvement of rubeosis from a single bevacizumab (Avastin) injection. Retina, 26:354–6. Flaxel CJ, Dustin L, Kim J, et al. 2007. Outcome of diabetic vitrectomy in Latino population. Retina, 27:1274–8. Grisanti S, Biester S, Peters S, et al. 2006. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol, 142:158–60. Liggett PE, Lean JS, Barlow WE, et al. 1987. Intraoperative argon endo- photocoagulation for recurrent vitreous hemorrhage after vitrectomy for diabetic retinopathy. Am J Ophthalmol, 103:146–9. Lee MS, Abrams GW. 2001. Membrane dissection in proliferative diabetic retinopathy. In: Peyman GA, Ameffert S, Conway MD, et al. (eds). Vit- reoretinal surgical techniques. London: Martin Dunitz Ltd, pp. 251–66. Meredith TA. 1994. Current indications for diabetic vitrectomy. In: Lewis H, Ryan SJ (eds). Medical and surgical retina: Advances, controversies and management. St. Louis: Mosby, pp. 290–303. Manzano RPA, Peyman GA, Khan P, et al. 2006. Testing intravitreal toxicity of bevacizumab (Avastin). Retina, 26:257–61. Mason JO, Colagross CT, Vail R. 2006. Diabetic vitrectomy: risks, prog- nosis, future trends. Curr Opin Ophthalmol, 17:281–5. Novak MA, Rice TA, Michels RG, et al. 1984. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology, 91:1485–9. Oshima Y, Sakagauchi H, Gomi F, et al. 2006. Regression of iris neovas- cularization after Intravitreal injection of bevacizumab in patients of proliferative diabetic retinopathy. Am J Ophthalmol, 142:155–8. Packer AJ, McCuen BJ, Hutton WL, et al. 1989. Procoagulant effect of intraocular sodium hyaluronate after phakic diabetic vitrectomy: a prospective randomized study. Ophthalmology, 96:1491–4 Pearson RV, McLeod D, Gregor ZJ. 1993. Removal of silicone oil following diabetic vitrectomy. Br J Ophthalmol, 77:204–7. Riedel KG, Gabel VP, Neubauer L, et al. 1990. Intravitreal silicone injection; complications and treatment of 415 consecutive patients. Graefes Arch Clin Exp Ophthalmol, 228:12–23. Rizzo S, Genosi-Ebert F, Di Bartolo E, et al. 2007. Injection of intravitreal Avastin before vitrectomy surgery in the treatment of proliferative dia- betic retinopathy [abstract]. Program and abstracts of “Cannes Retina Festival”; the joint meeting of the American Society of Retina Specialists and European Vitreoretinal Society, September 9–13, 2007; p. 140. Spaide RF, Fisher YL. 2006. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemor- rhage. Retina, 26:275–8. Scholda C, Rainer G, Kriechbaum K, et al. 2007. Preoperative intravitreal injection of bevacizumab in advanced proliferative diabetic retinopa- thy [abstract]. Joint Congress of SOE/AAO June 9–12, 2007, Vienna, Austria; p. 79. 715